AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32802833
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTA) combined with oral finasteride (FNS)
Trial: 32860964
Drug: Intermediate-high dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-high dose corticosteroids (IHDC)
Trial: 32860964
Drug: Pulse dose
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse dose corticosteroids (PDC)
Trial: 33577800
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg once daily for 35 days
Trial: 33906786
Drug: Radiological evaluation
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiological evaluation of implant position and mechanical axis in LM (+) group
Trial: 33906786
Drug: Radiological evaluation
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiological evaluation of implant position and mechanical axis in LM (−) group
Trial: 34609303
Drug: Proton-pump-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump-based triple therapy (PpTT) for 2 weeks
Trial: 34609303
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy for 2 weeks
Trial: 34609303
Drug: Proton-pump-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump-based triple therapy plus bovine lactoferrin for 2 weeks
Trial: 34609303
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy plus bovine lactoferrin for 2 weeks
Trial: 36175293
Drug: Romifidine IV
RxNorm normalized name: romifidine
DrugBank: Romifidine (DB11543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romifidine IV (80 μg kg–1 premedication, 40 μg kg–1 hour–1 maintenance, 20 μg kg–1 before recovery)
Trial: 36175293
Drug: Detomidine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine IV (15 μg kg–1 premedication, 5 μg kg–1 hour–1 maintenance, 2.5 μg kg–1 before recovery)
Trial: 36175293
Drug: Detomidine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine IV (15 μg kg–1 premedication, 5 μg kg–1 hour–1 maintenance, 5 μg kg–1 before recovery)
Trial: 34319275
Drug: Enteric-coated peppermint
RxNorm normalized name: Peppermint
DrugBank: Peppermint (DB10984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated peppermint oil 180 mg 3 times daily
Trial: 35943064
Drug: Therapist-assisted Internet-delivered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-assisted Internet-delivered cognitive therapy for SAD (OSCA)
Trial: 33857455
Drug: Staggered group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staggered group (single desynchronised monthly payments)
Trial: 33857455
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly synchronised payments)
Trial: 32114475
Drug: Extreme hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extreme hypofractionated radiotherapy with stereotactic body radiation therapy to 36.25 Gy/5# (7 to 10 days)
Trial: 33068641
Drug: Adrenaline dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline dosing and frequency
Trial: 33068641
Drug: Antihistamines and
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines and corticosteroids
Trial: 34238042
Drug: HF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF with assertive community treatment (HF-ACT)
Trial: 36173415
Drug: Romosozumab 210
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romosozumab 210 mg monthly for 12 months
Trial: 33395175
Drug: Topical silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silver sulfadiazine (SS) cream
Trial: 32814589
Drug: Horizontal sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horizontal sperm migration in injection dishes (Group B)
Trial: 35980316
Drug: Novel dental
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel dental gel containing 0.454% stannous fluoride and 2.6% EDTA
Trial: 32459643
Drug: Blended smoking
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended smoking cessation treatment (n=130)
Trial: 32459643
Drug: Face-to-face smoking
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face smoking cessation treatment (n=162)
Trial: 32459643
Drug: Face-to-face mode
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face mode of blended treatment
Trial: 32459643
Drug: Web mode
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Web mode of blended treatment
Trial: 32603632
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural treatment (ICBT), 8-week treatment
Trial: 36107429
Drug: MERM-observed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MERM-observed therapy (digital medication event reminder monitor); 15-day TB medication supply dispensed with a MERM device.
Trial: 36107429
Drug: Standard directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard directly observed therapy (DOT); in-person therapy.
Trial: 34195988
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) arm
Trial: 32545056
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy intervention
Trial: 34102559
Drug: Fortified group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified group 0 (FG0) - 0 mg/100 g bLF
Trial: 34102559
Drug: Fortified group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified group 1 (FG1) - 38 mg/100 g bLF
Trial: 34102559
Drug: Fortified group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified group 2 (FG2) - 76 mg/100 g bLF
Trial: 35304932
Drug: Papaverine (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (0.12 mg/ml, 1 ml)
Trial: 35304932
Drug: Heparin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (2 units/ml, 1 ml)
Trial: 35304932
Drug: Papaverine (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (0.12 mg/ml, 1 ml) as rescue treatment
Trial: 33596883
Drug: L-Carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine supplementation (1000 mg)
Trial: 32468749
Drug: 1st Generation
RxNorm normalized name: CEPHALOSPORIN 1ST GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st Generation Antipsychotics
Trial: 32468749
Drug: 2nd Generation
RxNorm normalized name: CEPHALOSPORIN 2ND GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2nd Generation Antipsychotics
Trial: 35218231
Drug: Foliglurax 10
RxNorm normalized name: Foliglurax
DrugBank: Foliglurax (DB15292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foliglurax 10 mg
Trial: 35218231
Drug: Foliglurax 30
RxNorm normalized name: Foliglurax
DrugBank: Foliglurax (DB15292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foliglurax 30 mg
Trial: 35738494
Drug: Macitentan (endothelin-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan (endothelin-1 receptor antagonist)
Trial: 33377921
Drug: Nitroglycerin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (5 μg/kg in 0.5 ml)
Trial: 32282432
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.5 ml)
Trial: 32627599
Drug: Penicillin G/Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin G/Hydrocortisone (PenGH)
Trial: 35123469
Drug: Adjusted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted treatment decision strategy including advice from a treatment algorithm
Trial: 33784968
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (ferric derisomaltose (FDI)) 1000 mg
Trial: 33784968
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (ferric derisomaltose (FDI))
Trial: 35293508
Drug: G1: 1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1: 1100 μg F/g, pH 4.5 (n = 76)
Trial: 35293508
Drug: G2: 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G2: 750 μg F/g, pH 4.5 (n = 74)
Trial: 35293508
Drug: G3: 1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G3: 1100 μg F/g, pH 7.0 (n = 78)
Trial: 33704351
Drug: Aflibercept (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks, as needed from 12 weeks onward)
Trial: 34000834
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (2 grams intravenous)
Trial: 34000834
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching intravenous)
Trial: 33234846
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for 4 cycles followed by nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity or a maximum of 48 weeks.
Trial: 33576394
Drug: Informational handout
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informational handout detailing U.S. Food and Drug Administration‐recommended ways to properly dispose of leftover opioids (n=188)
Trial: 33576394
Drug: Informational handout
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informational handout and a drug disposal kit with instructions on its use (n=170)
Trial: 32441668
Drug: Fenugreek 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek 400 mg/d
Trial: 32441668
Drug: Fenugreek 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek 500 mg/d
Trial: 35138350
Drug: Missing one
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missing one or more recommended medications
Trial: 36388925
Drug: Ulmus macrocarpa
RxNorm normalized name: Ulmus rubra pollen
DrugBank: Ulmus rubra pollen (DB10985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulmus macrocarpa Hance extract (UME) 500 mg (two capsules per day)
Trial: 36388925
Drug: Placebo (cornstarch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cornstarch, two capsules per day)
Trial: 36168678
Drug: Gore-Tex® thyroplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gore-Tex® thyroplasty with prior injection laryngoplasty (IL)
Trial: 36168678
Drug: Gore-Tex® thyroplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gore-Tex® thyroplasty without prior injection laryngoplasty (IL)
Trial: 32862469
Drug: Intravenous eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous eptinezumab 100 mg
Trial: 32862469
Drug: Intravenous eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous eptinezumab 300 mg
Trial: 33741668
Drug: Structured supervised
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured supervised exercise training consisting of three weekly exercise sessions
Trial: 32301053
Drug: Intradialytic combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic combined exercise (24-week, three times weekly, moderate-intensity)
Trial: 32506309
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of IBU/APAP 200 mg/500 mg
Trial: 32506309
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of IBU/APAP 250 mg/500 mg
Trial: 32506309
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of IBU/APAP 300 mg/500 mg
Trial: 35166009
Drug: Empagliflozin (10/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10/25 mg/day)
Trial: 33130153
Drug: Tailored cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored cognitive behavioral therapy (ADAPT) plus medical treatment as usual
Trial: 33130153
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment as usual only
Trial: 35909479
Drug: Posterior auricular
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior auricular injection (retroauricular group)
Trial: 35909479
Drug: Tympanum injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tympanum injection (tympanic group)
Trial: 32314939
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (GA) with patient‐controlled intravenous analgesia
Trial: 33539749
Drug: Short‐course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short‐course radiotherapy followed by chemotherapy before total mesorectal excision (TME)
Trial: 33539749
Drug: Preoperative chemoradiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy
Trial: 35286849
Drug: Placebo+Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo+Therapy
Trial: 36052360
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen 10 mg kg−1
Trial: 35862389
Drug: 200% recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200% recommended dose of fertilizer (RDF) with planting in the first week of October
Trial: 35862389
Drug: 200% recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200% recommended dose of fertilizer (RDF) with planting in the second week of October
Trial: 35862389
Drug: 150% recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150% recommended dose of fertilizer (RDF) with planting in the first week of October
Trial: 35862389
Drug: 100% recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% recommended dose of fertilizer (RDF) with planting in the first week of October
Trial: 35862389
Drug: 150% recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150% recommended dose of fertilizer (RDF) with planting in the first fortnight of October
Trial: 35862389
Drug: 150% recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150% recommended dose of fertilizer (RDF) with planting in the second week of October
Trial: 35862389
Drug: 100% recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% recommended dose of fertilizer (RDF) with planting in the first and second week of October
Trial: 34989804
Drug: Bevacizumab (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (1.25 mg/0.05 mL)
Trial: 35876254
Drug: Treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments
Trial: 34644619
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment/non-exercise)
Trial: 33573486
Drug: NPWT+ (Negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPWT+ (Negative Pressure Wound Therapy Plus)
Trial: 33573486
Drug: NPWT (Negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPWT (Negative Pressure Wound Therapy)
Trial: 33058694
Drug: CRTT‐L‐Cantonese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRTT‐L‐Cantonese
Trial: 33058694
Drug: CRTT‐R‐WF‐Cantonese and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRTT‐R‐WF‐Cantonese and CRTT‐L‐Cantonese
Trial: 33206786
Drug: Whole purple
RxNorm normalized name: Purple coneflower whole
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole purple grape juice (400 ml; 200 ml before and 200 ml after training)
Trial: 33206786
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (water; 400 ml; 200 ml before and 200 ml after training)
Trial: 32520900
Drug: Transdermal 17β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β estradiol (tE2) 50μg/d
Trial: 32520900
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (oCEE) 0.45mg/d
Trial: 32613644
Drug: Online Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Cognitive Behavioural Therapy (CBT)
Trial: 32118739
Drug: Fu's subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu's subcutaneous needling (FSN) therapy, 12 sessions over 3 weeks
Trial: 32118739
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy at specified points using acupuncture needles
Trial: 32118739
Drug: FSN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSN therapy
Trial: 35765921
Drug: 2-g intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g intravenous TXA
Trial: 35765921
Drug: 4-g intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-g intravenous TXA
Trial: 33583027
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of dexamethasone (12 mg intravenously daily for up to 10 days)
Trial: 33583027
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of dexamethasone (6 mg intravenously daily for up to 10 days)
Trial: 35477419
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity guideline only (control group G)
Trial: 32416983
Drug: Group 2T10I
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2T10I (screws tightened twice with a 10-minute interval)
Trial: 32416983
Drug: Group 2T0I
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2T0I (screws tightened twice with no interval)
Trial: 34706691
Drug: Psychodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic therapy (PDT)
Trial: 36271193
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment intensity (average 3.7 ± 2.6 equivalent medications at usual dosages)
Trial: 32564693
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system inhibitors
Trial: 36082154
Drug: Handgrip-strengthening exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handgrip-strengthening exercises (HGSE) added to conventional therapy
Trial: 36082154
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (ultrasound therapy, ice, and stretching exercises)
Trial: 32681996
Drug: Auto-cross-linked hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auto-cross-linked hyaluronic acid gel after surgery
Trial: 34351452
Drug: Volumetric modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volumetric modulated arc therapy (VMAT) with two small tangential subarcs
Trial: 32227754
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy (initial angiography and revascularization plus guideline‐based medical therapy)
Trial: 32227754
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy (guideline‐based medical therapy alone)
Trial: 35667065
Drug: Molnupiravir, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir, 800 mg, every 12 hours for 5 days
Trial: 34914219
Drug: Pressing acupuncture
RxNorm normalized name: LEMON OIL, COLD PRESSED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressing acupuncture therapy (PAT) combined with auricular pressure beans
Trial: 34914219
Drug: Auricular pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular pressure beans combined with drug therapy
Trial: 33400434
Drug: r-TMS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-TMS (5 Hz, 20-minute daily session, 5 days per week, for a total of 10 sessions)